Lipocine Inc (LPCN) slumped after opening sharply higher today. The stock rallied in the pre-market due to the company releasing a report detailing apparently positive indications for LPCN for its potential in the treatment of liver fat in hypogonadal males. However, biotech columnist Adam Feuerstein voiced negative comments, stating that he believes the study was not conducted properly and therefore questions the validity of the results. Here’s a recap.
Oil is rising, the 10-year yield is approaching 5%, and the Fed is likely hiking again next week. Scott Bauer joined Business First AM to share the trading mindset he falls back on when there is simply too much the market does not know yet.
Read Article
Mike Shorr joined Benzinga’s morning show for a wide-ranging look at the week ahead, from a slow post-Labor Day start to why he thinks one overlooked economic report matters more than the one everyone talks about.
Read Article
After dropping on Friday ahead of the holiday weekend, the S&P 500 ended the week with a slim gain and was about 1% shy of its mid-August record high. Equities were jostled by changes in rate-path expectations and concerns that rising U.S. Treasury yields could trip up Wall Street’s rally. Markets have been consumed in recent […]
Read Article
Scott Bauer joined the IBKR Podcast this week to break down what moved markets last week and what investors need to watch heading into the next stretch of earnings season. From lagging inflation data to big tech CapEx concerns, Scott did not hold back.
Read Article
The Dow rose more than 1% to a record closing high on Thursday ahead of the long holiday weekend as a softer-than-expected U.S. jobs report eased worries about interest rate hikes, while another sharp drop in chipmaker stocks weighed on the Nasdaq. The second half of 2026 kicked off this week much the same as […]
Read Article
A renewed sell-off in technology stocks grabbed headlines this week. The Nasdaq index fell 4.5%, closing lower 5 days in a row, led by a large 5.5% decline in the so-called Magnificent 7 mega cap names. Meanwhile, the post IPO exuberance around SpaceX appears to be fading, with shares now down 25% from their peak. […]
Read ArticleWe choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.